Clinical Trial Update: Nicotinic Receptors and Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial investigating nicotinic receptor targets for schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: VA Office of Research and Development | Conditions: Schizophrenia | Phase 1, Phase 2 | Status: WITHDRAWN